Pacific Biosciences Of California (PACB) Depreciation & Amortization (CF) (2010 - 2026)

Pacific Biosciences Of California has reported Depreciation & Amortization (CF) for 17 years, with the latest figure at $2.2 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 57.12% year-over-year to $2.2 million; the trailing twelve-month figure through Mar 2026 stood at $10.1 million (down 35.72% YoY), and the FY2025 full-year result was $13.0 million, down 5.62% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $2.2 million, down from $2.7 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $5.1 million in Q1 2025, with the low at $2.2 million in Q1 2026.
• Average Depreciation & Amortization (CF) over 5 years is $2.9 million, with a median of $2.8 million recorded in 2023.
• Year-over-year, Depreciation & Amortization (CF) surged 58.36% in 2025 and slumped 57.12% in 2026.
• Tracing PACB's Depreciation & Amortization (CF) over 5 years: stood at $2.6 million in 2022, then rose by 17.56% to $3.0 million in 2023, then decreased by 5.68% to $2.8 million in 2024, then decreased by 3.27% to $2.7 million in 2025, then retreated by 19.97% to $2.2 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $2.2 million (Q1 2026), $2.7 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.

Peer Comparison